Rose McNulty

Scott Soefje, PharmD, outlines proactive financial screening, flexible payment models, and stronger academic-community partnerships for advanced cancer care.

The most-read articles focused on soft tissue sarcoma research, including innovative biomarkers, treatment strategies, and multidisciplinary care challenges.

The 2025 Community Oncology Conference, hosted by COA, reflected a commitment to patient-centered care, access, and innovation in community oncology.

In-home step training for multiple sclerosis showed no improvement in ankle proprioception or muscle performance, highlighting challenges in exercise adherence.

Explore the latest breakthroughs in allergy treatments, including FDA approvals and emerging therapies that enhance patient care and address systemic challenges.

Scott Soefje, PharmD, MBA, BCOP, of Mayo Clinic, discusses how payer-provider collaboration and pharmacist-led management can help improve oncology care.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

The 2025 American Thoracic Society International Conference brought advancements in pulmonary medicine and highlighted the need for health equity reforms.

Community oncology practices can enhance their presence in the community by offering innovative service lines such as multispecialty infusions, and by offering enrollment assistance for better outcomes.

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL compared with bendamustine plus rituximab.

Academic and clinical experts convened in New Haven, Connecticut, on October 30, 2025, to discuss the potential of coordinated care and prevention to manage cardio-renal-metabolic (CRM) disease.

Ryan Haumschild, PharmD, discusses overcoming barriers to cancer care access, emphasizing the role of pharmacy in improving access and affordability.

New treatment options for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could enhance patient care and monitoring.

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed key aspects of the KEYNOTE-B96 trial of paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

Ryan Haumschild, PharmD, MS, MBA, discusses key considerations for pharmacists to ensure access to cutting-edge therapies for patients with cancer.

The latest advancements in idiopathic pulmonary fibrosis (IPF) treatment offer promising efficacy and improved tolerability.

Early diagnosis and treatment are crucial for managing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, yet barriers hinder timely intervention.

Remibrutinib demonstrated rapid and sustained symptom relief for chronic spontaneous urticaria in a pooled analysis of REMIX-1 and REMIX-2.

Urticaria symptom reduction with remibrutinib was linked with improved quality of life and sleep for patients with chronic spontaneous urticaria.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Remibrutinib shows rapid and sustained relief for chronic spontaneous urticaria, offering a promising oral treatment option for patients.

Plozasiran gains FDA approval as the first treatment for familial chylomicronemia syndrome based on phase 3 PALISADE data.

Experts discuss the urgent need for equitable access to cancer care, addressing barriers in treatment delivery and the importance of personalized medicine.

Experts discuss the intersection of innovation, affordability, and access in cancer care, focusing on multiple myeloma and NSCLC advancements.

Ritlecitinib significantly improves hair regrowth and reduces psychosocial burdens in patients with alopecia areata, enhancing emotional well-being over time.

Key factors influencing chronic urticaria duration highlight the importance of early identification and management in primary care settings.

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for beneficiaries starting in 2026.

The White House announced significant drug pricing cuts for GLP-1s for diabetes and obesity for Medicare and Medicaid beneficiaries and on TrumpRx.

In the phase 3 BRAVE-AA-PEDS trial, baricitinib led to significant scalp, eyelash, and eyebrow hair regrowth at 1 year in adolescents with alopecia areata.